Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLB-COV2-043 COVID-19 Booster Study
NCT05602961Phase 2Withdrawn
- Sponsor
- GreenLight Biosciences
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 2, randomised, single-blind trial of GLB-COV2-043 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by GreenLight Biosciences. Primary endpoints: Safety, including reactogenicity and Immunogenicity- neutralizing antibody response. Planned start Feb 2023; status: withdrawn.
02
Drugs
GLB-COV2-043
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05602961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602961.